Why the study?
AMI can rarely arise from non-lipid-rich coronary plaques, but post-PCI clinical outcomes compared to lipid-rich lesions remained unclear.
Does the presence of non-lipid-rich plaque (maxLCBI4mm < 400) compared to lipid-rich plaque (maxLCBI4mm ≥ 400) in infarct-related lesions predict better clinical outcomes in AMI patients undergoing PCI?
Does the presence of non-lipid-rich plaque (maxLCBI4mm < 400) compared to lipid-rich plaque (maxLCBI4mm ≥ 400) in infarct-related lesions predict better clinical outcomes in AMI patients undergoing PCI?
In AMI patients undergoing PCI, non-lipid-rich infarct-related plaques (maxLCBI4mm < 400) assessed by NIRS-IVUS are associated with significantly better long-term clinical outcomes compared to lipid-rich plaques.
Answers are grounded in this paper and cite their sources.
Non-lipid-rich plaques associated with lower MACE after AMI PCI; hypothesis-generating for NIRS-IVUS risk stratification.
Acute myocardial infarction (AMI) can rarely arise from non-lipid-rich coronary plaques. This study sought to compare the clinical outcomes after percutaneous coronary intervention (PCI) between AMI showing maximum lipid-core burden index in 4 mm (maxLCBI4mm) < 400 and ≥ 400 in the infarct-related lesions assessed by near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS). We investigated 426 AMI patients who underwent NIRS-IVUS in the infarct-related lesions before PCI. Major adverse cardiovascular events (MACE) were defined as the composite of cardiac death, non-fatal MI, clinically driven target lesion revascularization (TLR), clinically driven non-TLR, and congestive heart failure requiring hospitalization. 107 (25%) patients had infarct-related lesions of maxLCBI4mm < 400, and 319 (75%) patients had those of maxLCBI4mm ≥ 400. The maxLCBI4mm < 400 group had a younger median age at onset (68 years [IQR: 57-78 years] vs. 73 years [IQR: 64-80 years], P = 0.007), less frequent multivessel disease (39% vs. 51%, P = 0.029), less frequent TIMI flow grade 0 or 1 before PCI (62% vs. 75%, P = 0.007), and less frequent no-reflow immediately after PCI (5% vs. 11%, P = 0.039). During a median follow-up period of 31 months [IQR: 19-48 months], the frequency of MACE was significantly lower in the maxLCBI4mm < 400 group compared with the maxLCBI4mm ≥ 400 group (4.7% vs. 17.2%, P = 0.001). MaxLCBI4mm < 400 was an independent predictor of MACE-free survival at multivariable analysis (hazard ratio: 0.36 [confidence interval: 0.13-0.98], P = 0.046). MaxLCBI4mm < 400 measured by NIRS in the infract-related lesions before PCI was associated with better long-term clinical outcomes in AMI patients.
No takes yet. Share an insight, caveat, or question.
Terada et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: